Archive \ Volume.15 2024 Issue 3

Long-term Outcome in Patients with Turner Syndrome – Retrospective Study

Codruta Diana Petchesi , Alin Remus Iuhas , Ramona Hodisan*✉ , Dana Carmen Zaha , Alexandru Daniel Jurca
  1. Department of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania.
  2. Regional Center for Medical Genetics Bihor (part of ERN THACA), Emergency Clinical County Hospital Bihor, Oradea, Romania.
  3. Emergency Clinical County Hospital Bihor, Oradea, Romania.

  4. Department of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania. 


Abstract

Turner syndrome is one of the most frequent chromosomal disorders and has an increased associated morbidity. The clinical picture of Turner syndrome reveals itself gradually, not every patient exhibits the full clinical picture, but gonadal dysgenesis and short stature are invariably present. We describe the long-term outcomes in a cohort of 41 patients with Turner syndrome followed at the Regional Center for Medical Genetics Bihor. A retrospective study was performed using the medical records; epidemiological, clinical, laboratory, cytogenetic, and imaging data were analyzed. The frequency of congenital heart abnormalities and intellectual disability was increased in the study group, necessitating a more effective screening technique in our country, to identify all the cases with TS. Early diagnosis and hormonal treatment are critical for a patient's favorable prognosis in stature, bone metabolism, cardiovascular system, and quality of life. Patients with TS have higher rates of related morbidity, especially skeletal, kidney, ophthalmological, and dermatological and a multidisciplinary team is essential for the management of TS cases.


Downloads: 150
Views: 647

How to cite:
Vancouver
Petchesi CD, Iuhas AR, Hodisan R, Zaha DC, Jurca AD. Long-term Outcome in Patients with Turner Syndrome – Retrospective Study. Arch Pharm Pract. 2024;15(3):54-7. https://doi.org/10.51847/dfg57HvhDj
APA
Petchesi, C. D., Iuhas, A. R., Hodisan, R., Zaha, D. C., & Jurca, A. D. (2024). Long-term Outcome in Patients with Turner Syndrome – Retrospective Study. Archives of Pharmacy Practice, 15(3), 54-57. https://doi.org/10.51847/dfg57HvhDj

Download Citation
References
  1. Cui X, Cui Y, Shi L, Luan J, Zhou X, Han J. A basic understanding of turner syndrome: Incidence, complications, diagnosis, and treatment. Intractable Rare Dis Res. 2018;7(4):223-8.  doi:10.1097/GIM.0b013e3181c684b2
  2. Medial Home Portal. [Internet]. Turner Syndrome. 2019 [updated 2019 August; cited 2024 Apr 25]. Available from: https://www.medicalhomeportal.org/diagnoses-and-conditions/turner-syndrome#SectionPracticeGuidelines
  3. Morgan T. Turner syndrome: Diagnosis and management. Am Fam Physician. 2007;76(3):405-17.
  4. Gravholt CH, Andersen NH, Conway GS, Dekkers OM, Geffner ME, Klein KO, et al. Clinical practice guidelines for the care of girls and women with turner syndrome: Proceedings from the 2016 cincinnati international turner syndrome meeting. Eur J Endocrinol. 2017;177(3):G1-70. doi:10.1530/EJE-17-0430
  5. Jurcă MC, Bembea M, Iuhas OA, Kozma K, Petcheşi CD, Jurcă AD, et al. Double autosomal trisomy with mosaicism 47, XY (+ 8)/47, XY (+ 21). Morphological and genetic changes of a rare case. Rom J Morphol Embryol. 2018;59(3):985-8.
  6. Spinella F, Fiorentino F, Biricik A, Bono S, Ruberti A, Cotroneo E, et al. Extent of chromosomal mosaicism influences the clinical outcome of in vitro fertilization treatments. Fertil Steril. 2018;109(1):77-83. doi:10.1016/j.fertnstert.2017.09.025
  7. National Library of Medicine. [Internet]. Turner syndrome. 2023 [updated 2023 August 8; cited 2024 Apr 25]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554621
  8. Medscape. [Internet]. Turner syndrome [updated 2021 March 19; cited 2024 Apr 25]. Available from: https://emedicine.medscape.com/article/949681-overview?&icd=login_success_email_match_fpf
  9. Ross JL, Quigley CA, Cao D, Feuillan P, Kowal K, Chipman JJ, et al. Growth hormone plus childhood low-dose estrogen in turner's syndrome. N Engl J Med. 2011;364(13):1230-42. doi:10.1056/NEJMoa1005669
  10. Simm D, Degenhardt K, Gerdemann C, Völkl TM, Rauch A, Dörr HG. Chronological age of patients with turner syndrome at diagnosis. Klin Padiatr. 2007;220(1):16-20. doi:10.1055/s-2007-972569
  11. Swauger S, Backeljauw P, Hornung L, Shafer J, Casnellie L, Gutmark-Little I. Age at and indication for diagnosis of turner syndrome in the pediatric population. Am J Med Genet A. 2021;185(11):3411-7. doi:10.1002/ajmg.a.62459
  12. Chiang T, Schultz RM, Lampson MA. Meiotic origins of maternal age-related aneuploidy. Biol Reprod. 2012;86(1):1-7. doi:10.1095/biolreprod.111.094367
  13. Mikwar M, MacFarlane AJ, Marchetti F. Mechanisms of oocyte aneuploidy associated with advanced maternal age. Mutat Res Rev Mutat Res. 2020;785:108320. doi:10.1016/j.mrrev.2020.108320
  14. Fuchs MM, Attenhofer Jost C, Babovic-Vuksanovic D, Connolly HM, Egbe A. Long-term outcomes in patients with turner syndrome: A 68-year follow-up. J Am Heart Assoc. 2019;8(11):e011501. doi:10.1161/JAHA.118.011501
  15. Chacko EM, Rapaport R. Short stature and its treatment in turner and Noonan syndromes. Curr Opin Endocrinol Diabetes Obes. 2012;19(1):40-6. doi:10.1097/MED.0b013e32834ed64e
  16. Dantas NCB, Braz AF, Malaquias A, Lemos-Marini S, Arnhold IJP, Silveira ER, et al. Adult height in 299 patients with turner syndrome with or without growth hormone therapy: Results and literature review. Horm Res Paediatr. 2021;94(1-2):63-70. doi:10.1159/000516869
  17. Gnacińska M, Magnuszewska H, Sworczak K. Metabolic consequences of recombinant human growth hormone therapy in patients with turner syndrome. Pediatr Endocrinol Diabetes Metab. 2023;29(1):16-21. doi:10.5114/pedm.2022.123204
  18. Backeljauw P, Blair JC, Ferran JM, Kelepouris N, Miller BS, Pietropoli A, et al. Early GH treatment is effective and well tolerated in children with turner syndrome: NordiNet® IOS and answer program. J Clin Endocrinol Metab. 2023;108(10):2653-65. doi:10.1210/clinem/dgad159
  19. Backeljauw P, Kanumakala S, Loche S, Schwab KO, Pfäffle RW, Höybye C, et al. Safety and effectiveness of recombinant human growth hormone in children with turner syndrome: Data from the patro children study. Horm Res Paediatr. 2021;94(3-4):133-43. doi:10.1159/000515875
  20. Aly J, Kruszka P. Novel insights in turner syndrome. Curr Opin Pediatr. 2022;34(4):447-60. doi:10.1097/MOP.0000000000001135 
  21. Iuhas A, Jurca C, Kozma K, Riza AL, Streață I, Petcheși C, et al. PAH pathogenic variants and clinical correlations in a group of Hyperphenylalaninemia patients from North-Western Romania. Diagnostics (Basel). 2023;13(8):1483. doi:10.3390/diagnostics13081483
  22. Kim S, Kim H, Lee I, Choi E, Baek J, Lee J, et al. Effects of hormone replacement therapy on bone mineral density in Korean adults with turner syndrome. J Korean Med Sci. 2024;39(1):e9. doi:10.3346/jkms.2024.39.e9
  23. Giordano R, Forno D, Lanfranco F, Manieri C, Ghizzoni L, Ghigo E. Metabolic and cardiovascular outcomes in a group of adult patients with turner's syndrome under hormonal replacement therapy. Eur J Endocrinol. 2011;164(5):819-26. doi:10.1530/EJE-11-0002
  24. Jordan TL, Klabunde M, Green T, Hong DS, Ross JL, Jo B, et al. Longitudinal investigation of cognition, social competence, and anxiety in children and adolescents with turner syndrome. Horm Behav. 2023;149:105300. doi:10.1016/j.yhbeh.2022.105300
  25. Klein KO, Rosenfield RL, Santen RJ, Gawlik AM, Backeljauw PF, Gravholt CH, et al. Estrogen replacement in turner syndrome: Literature review and practical considerations. J Clin Endocrinol Metab. 2018;103(5):1790-803. 
  26. Mitsch C, Alexandrou E, Norris AW, Pinnaro CT. Hyperglycemia in turner syndrome: Impact, mechanisms, and areas for future research. Front Endocrinol (Lausanne). 2023;14:1116889. doi:10.3389/fendo.2023.1116889

 

 

 


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.